Skip to main content

The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean Nam, PhD, of Qurient; Sharanya Nag, PhD, of Memorial Sloan Kettering Cancer Center; and Giuseppina Carbone, MD, about their innovative strategies to inhibit KRAS, enhance antibody-drug conjugate efficacy, and tackle resistance.

The post From the Bench, AACR D3 2026: Emerging Therapeutic Strategies to Inhibit KRAS, Enhance ADCs, and Tackle Resistance appeared first on American Association for Cancer Research (AACR).

Source: Oncology

Read More